贝鲁单抗治疗近期诊断的系统性红斑狼疮的短期临床观察。
Short-term clinical observations of belimumab in the treatment of recently diagnosed systemic lupus erythematosus.
机构信息
Department of Immunology, The Tianjin First Central Hospital, Tianjin, China.
出版信息
Immun Inflamm Dis. 2022 Nov;10(11):e716. doi: 10.1002/iid3.716.
OBJECTIVE
To explore the therapeutic effectiveness and safety of belimumab in the treatment of recently diagnosed systemic lupus erythematosus (SLE).
METHODS
Between January 2019 and February 2022, a total of 30 patients who had been recently diagnosed with SLE were selected for 6 months of belimumab treatment at the Department of Rheumatology and Immunology, Tianjin First Central Hospital. Laboratory test results and related adverse reactions were recorded at baseline and after treatment.
RESULTS
Participants' white blood cell counts and complement 3, complement 4, and hemoglobin levels were higher after treatment than at baseline. Participants' immunoglobulin G and immunoglobulin M levels, SLE Disease Activity Index 2000 scores, glucocorticoid doses, erythrocyte sedimentation rates, and serum albumin/globulin ratios were lower after treatment. These differences were all statistically significant (p < .05).
CONCLUSION
Belimumab was safe and effective in patients recently diagnosed with SLE and might help to reduce the use of glucocorticoids and to improve anemia with few adverse reactions. Belimumab might be applied in the treatment of patients recently diagnosed with SLE with high disease activity.
目的
探讨贝利尤单抗治疗新诊断系统性红斑狼疮（SLE）的疗效和安全性。
方法
选取 2019 年 1 月至 2022 年 2 月于天津市第一中心医院风湿免疫科接受贝利尤单抗治疗的 30 例新诊断 SLE 患者，进行为期 6 个月的治疗。记录患者治疗前后的实验室检查结果及相关不良反应。
结果
治疗后患者的白细胞计数、补体 3、补体 4 和血红蛋白水平高于治疗前。治疗后患者的免疫球蛋白 G、免疫球蛋白 M、SLE 疾病活动度 2000 评分、糖皮质激素剂量、红细胞沉降率和血清白蛋白/球蛋白比值均低于治疗前，差异均有统计学意义（p＜0.05）。
结论
贝利尤单抗治疗新诊断的 SLE 患者安全有效，有助于减少糖皮质激素的使用，改善贫血，不良反应少。贝利尤单抗可应用于高疾病活动度的新诊断 SLE 患者的治疗。
Zotero 插件